World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
119
Citations
65635
World Ranking
3840
National Ranking
2103

Research.com Recognitions

  • 2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Mark E. Robson is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research work spans a range of topics primarily centered on cancer genomics, diagnostics, and targeted therapies, with a significant emphasis on breast cancer and genetic factors influencing cancer development and treatment.

The scientist's publication record includes important contributions in leading journals. The most frequently appearing publication venues include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • npj Breast Cancer
  • Clinical Cancer Research

Their main fields of study are Medicine and Biochemistry, Genetics and Molecular Biology. Within these broader categories, subfields of focus include:

  • Genetics
  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Molecular Biology

Mark E. Robson's work addresses several key topics in cancer research and therapy, notably:

  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • PARP inhibition in cancer therapy
  • Genetic factors in colorectal cancer
  • HER2/EGFR in Cancer Research

Key recent papers authored include:

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology
  • Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group, 2020, Annals of Oncology
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis, 2020, Nature Genetics
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients, 2022, Cell
  • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes, 2020, Journal of Clinical Oncology

Frequent collaborators in their research include Kenneth Offit, Pedram Razavi, Susan M. Domchek, Zsofia K. Stadler, and Sarat Chandarlapaty, reflecting sustained partnerships on numerous research projects and publications.

In recognition of their contributions, Mark E. Robson was elected a Fellow of the American Association for the Advancement of Science (AAAS) in 2012.

Best Publications

  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed

  • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer

    A Tutt;M Robson;J E Garber;S M Domchek

  • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

    Noah D. Kauff;Jaya M. Satagopan;Mark E. Robson;Lauren Scheuer

  • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

    Colin C. Pritchard;Joaquin Mateo;Michael F. Walsh;Navonil De Sarkar

  • Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

    Douglas Frederick Easton;Paul David Pharoah;Antonis C. Antoniou;Marc Derek Tischkowitz

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

    F. Mosele;J. Remon;J. Mateo;C. B. Westphalen

  • The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

    Pedram Razavi;Matthew T. Chang;Guotai Xu;Chaitanya Bandlamudi

  • American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

    Mark E. Robson;Mark E. Robson;Angela R. Bradbury;Banu K Arun;Susan M. Domchek

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • A note on competing risks in survival data analysis

    J M Satagopan;L Ben-Porat;M Berwick;M Robson

  • Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

    Nasim Mavaddat;Daniel Barrowdale;Irene L. Andrulis;Susan M. Domchek

  • Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

    Catherine C. Coombs;Ahmet Zehir;Sean M. Devlin;Ashwin Kishtagari

  • Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study

    Noah D. Kauff;Susan M. Domchek;Tara M. Friebel;Mark E. Robson

  • Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study

    Steven A. Narod;Jean Sébastien Brunet;Parviz Ghadirian;Mark Robson

  • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    M.E. Robson;N. Tung;P. Conte;S.-A. Im

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

    Nasim Mavaddat;Paul D.P. Pharoah;Kyriaki Michailidou;Jonathan Tyrer

Frequent Co-Authors

Kenneth Offit
Kenneth Offit Memorial Sloan Kettering Cancer Center
Susan M. Domchek
Susan M. Domchek University of Pennsylvania
Judy Garber
Judy Garber Harvard University
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Fergus J. Couch
Fergus J. Couch Mayo Clinic
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Jeffrey N. Weitzel
Jeffrey N. Weitzel Natera (United States)
Irene L. Andrulis
Irene L. Andrulis University of Toronto
Katherine L. Nathanson
Katherine L. Nathanson University of Pennsylvania
Nadine Tung
Nadine Tung Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have more flexible options to begin or enhance their careers. Beyond the traditional MD path, a variety of online degrees offer specialized roles within the healthcare sector. For those interested in pharmacy, pursuing an online pharmd provides clinical training and can lead to sought-after positions in pharmacies or healthcare organizations.

The rising demand for digital health records has opened opportunities in healthcare informatics degree programs. Graduates often work to ensure patient data is accurate and secure.

If you are curious about administration, programs teaching how much does it cost to become a medical coder cover affordable ways to enter the field, with quick entry into healthcare billing roles.

Nursing remains a cornerstone of healthcare. For RNs ready to advance, cheap np programs make it possible to become a nurse practitioner without a heavy financial burden.

Exploring these pathways can help you find rewarding, in-demand careers that fit your interests and schedule.

Best Scientists Citing Mark E. Robson

Trending Scientists

Recently Published Articles